EVOLVING PARADIGM: Allison Rosenberg of the Government-University-Industry Roundtable feels the insider-trading case reflects changes in drug research funding. |
However, other observers argue the case simply illustrates that researchers are no different from anyone when it comes to the rules of investment. In addition, some say it is yet another aspect of the increasingly discussed issue of industry-funded research (K.Y. Kreeger, The...
Interested in reading more?
Become a Member of
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!